# Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics

> **NCT02619162** · PHASE1 · COMPLETED · sponsor: **Centro Nacional de Investigaciones Oncologicas CARLOS III** · enrollment: 25 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Nintedanib
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT02619162
- **Lead sponsor:** Centro Nacional de Investigaciones Oncologicas CARLOS III
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2017-11
- **Final completion:** 2018-06
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2019-07-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02619162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02619162, "Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT02619162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*